← Back to Search

Chemotherapy

Nivolumab + Ipilimumab + Azacitidine for Myelodysplastic Syndrome

Phase 2

Waitlist Available

Led By Guillermo Garcia-Manero

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Previously untreated

Eastern Cooperative Oncology Group (ECOG) performance status =< 2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 weeks

Awards & highlights

Study Summary

This trial studies the side effects of nivolumab and/or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome.

Who is the study for?

This trial is for adults with Myelodysplastic Syndrome (MDS) who have previously been treated with hypomethylating agents but didn't respond well or the disease came back. They should not have had a stem cell transplant, any other cancer treatments, or major surgery within 2 weeks before starting the study. Participants need to be relatively healthy otherwise and can't be pregnant, breastfeeding, or have certain autoimmune diseases.Check my eligibility

What is being tested?

The trial is testing how effective and safe it is to use Nivolumab and/or Ipilimumab with or without Azacitidine in treating MDS. These drugs include monoclonal antibodies that may block cancer growth by targeting specific cells and chemotherapy that stops cancer cells from growing.See study design

What are the potential side effects?

Possible side effects include immune-related reactions like inflammation of organs, skin rash, hormone gland problems (like thyroid), liver issues; infusion reactions; tiredness; nausea; blood count changes increasing infection risk; potential harm to an unborn baby.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have not received any treatment for my condition.

Select...

I can take care of myself and am up and about more than half of my waking hours.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Response Rate (ORR) in MDS Participants Who Have Not Received Hypomethylating Agents

Muscular Dystrophy

Trial Design

6Treatment groups

Experimental Treatment

Group I: Cohort VI (azacitidine, nivolumab, ipilimumab)Experimental Treatment4 Interventions

Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 6. Treatment with ipilimumab repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Cycles with nivolumab and azacitidine repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Group II: Cohort V (azacitidine, ipilimumab)Experimental Treatment3 Interventions

Patients receive azacitidine IV over 10-40 minutes on days 1-5 and ipilimumab IV over 30 minutes on day 6. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Group III: Cohort IV (azacitidine, nivolumab)Experimental Treatment3 Interventions

Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes on days 6 and 20. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Group IV: Cohort III (nivolumab, ipilimumab)Experimental Treatment3 Interventions

Patients receive nivolumab IV over 30 minutes on days 1 and 15 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes every 2 weeks (or every 4 weeks if patients receive azacitidine) in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab, nivolumab, and azacitidine at the discretion of the treating physician.

Group V: Cohort II (ipilimumab)Experimental Treatment2 Interventions

Patients receive ipilimumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab and azacitidine at the discretion of the treating physician.

Group VI: Cohort I (nivolumab)Experimental Treatment2 Interventions

Patients receive nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive nivolumab and azacitidine at the discretion of the treating physician.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Azacitidine

FDA approved

Ipilimumab

FDA approved

Nivolumab

FDA approved

0 / 2Eligibility criteria met